Candela's ALEXlazr cleared by FDA:
This article was originally published in Clinica
Candela's ALEXlazr has been cleared by the US FDA for treating pigmented skin lesions. Such lesions are commonly caused by sun exposure and sun damage. The device had previously been cleared for removing tattoos and pigmented dermal lesions. The treatment costs between $100 and $400 per session. The company based in Wayland, Massachusetts, estimates the potential worldwide market to be $2,000 million with over 28 million people in the US alone requiring the treatment.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.